Cereno Scientific and Abbott enter collaboration for use of cutting-edge monitor device in upcoming Phase II study with CS1
Cereno Scientific (XSAT: CRNO B) today announced that a collaboration agreement has been entered with global healthcare company Abbott regarding use of its CardioMEMS™ HF System in the upcoming Phase II study with Cereno’s drug candidate CS1. The technology will be used to remotely and continously monitor the pulmonary pressure in the Phase II study evaluating CS1 for the treatment of pulmonary arterial hypertension (PAH). The CardioMEMS device allows Cereno to use a smaller-sized patient population for the Phase II study, which is both more time and cost efficient.“We are passionate about